Equity Overview
Price & Market Data
Price: $16.85
Daily Change: -$0.25 / 1.48%
Range: $15.84 - $17.30
Market Cap: $128,692,720
Volume: 39,659
Performance Metrics
1 Week: 3.76%
1 Month: 39.14%
3 Months: 55.16%
6 Months: 4.59%
1 Year: 9.20%
YTD: 6.78%
Company Details
Employees: 73
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study. The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.